These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 17080752)

  • 1. Identifying the most successful dose (MSD) in dose-finding studies in cancer.
    Zohar S; O'Quigley J
    Pharm Stat; 2006; 5(3):187-99. PubMed ID: 17080752
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimal designs for estimating the most successful dose.
    Zohar S; O'Quigley J
    Stat Med; 2006 Dec; 25(24):4311-20. PubMed ID: 16969893
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sensitivity of dose-finding studies to observation errors.
    Zohar S; O'Quigley J
    Contemp Clin Trials; 2009 Nov; 30(6):523-30. PubMed ID: 19580886
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Retrospective robustness of the continual reassessment method.
    O'Quigley J; Zohar S
    J Biopharm Stat; 2010 Sep; 20(5):1013-25. PubMed ID: 20721788
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dose-escalation designs in oncology: ADEPT and the CRM.
    Shu J; O'Quigley J
    Stat Med; 2008 Nov; 27(26):5345-53; discussion 5354-5. PubMed ID: 18752259
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Case Example of Dose Optimization Using Data From Bortezomib Dose-Finding Clinical Trials.
    Lee SM; Backenroth D; Cheung YK; Hershman DL; Vulih D; Anderson B; Ivy P; Minasian L
    J Clin Oncol; 2016 Apr; 34(12):1395-401. PubMed ID: 26926682
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interval estimates of the probability of toxicity at the maximum tolerated dose for small samples.
    Natarajan L; O'Quigley J
    Stat Med; 2003 Jun; 22(11):1829-36. PubMed ID: 12754718
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dose-finding designs: the role of convergence properties.
    Oron AP; Azriel D; Hoff PD
    Int J Biostat; 2011 Oct; 7():Article 39. PubMed ID: 22718676
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Finding the right dose for cancer therapeutics--can we do better?
    Rubin EH; Anderson KM
    Clin Cancer Res; 2010 Feb; 16(4):1085-7. PubMed ID: 20145182
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dose finding with continuous outcome in phase I oncology trials.
    Wang Y; Ivanova A
    Pharm Stat; 2015; 14(2):102-7. PubMed ID: 25408518
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Towards new methods for the determination of dose limiting toxicities and the assessment of the recommended dose for further studies of molecularly targeted agents--dose-Limiting Toxicity and Toxicity Assessment Recommendation Group for Early Trials of Targeted therapies, an European Organisation for Research and Treatment of Cancer-led study.
    Postel-Vinay S; Collette L; Paoletti X; Rizzo E; Massard C; Olmos D; Fowst C; Levy B; Mancini P; Lacombe D; Ivy P; Seymour L; Le Tourneau C; Siu LL; Kaye SB; Verweij J; Soria JC
    Eur J Cancer; 2014 Aug; 50(12):2040-9. PubMed ID: 24880774
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adaptive designs for identifying optimal biological dose for molecularly targeted agents.
    Zang Y; Lee JJ; Yuan Y
    Clin Trials; 2014 Jun; 11(3):319-327. PubMed ID: 24844841
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An adaptive dose-finding approach for correlated bivariate binary and continuous outcomes in phase I oncology trials.
    Hirakawa A
    Stat Med; 2012 Mar; 31(6):516-32. PubMed ID: 22108785
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New paradigm in dose-finding trials: patient-specific dosing and beyond phase I.
    Rogatko A; Babb JS; Tighiouart M; Khuri FR; Hudes G
    Clin Cancer Res; 2005 Aug; 11(15):5342-6. PubMed ID: 16061846
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Estimating the probability of toxicity at the recommended dose following a phase I clinical trial in cancer.
    O'Quigley J
    Biometrics; 1992 Sep; 48(3):853-62. PubMed ID: 1420845
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A non-parametric approach to the design and analysis of two-dimensional dose-finding trials.
    Ivanova A; Wang K
    Stat Med; 2004 Jun; 23(12):1861-70. PubMed ID: 15195320
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A two-dimensional search algorithm for dose-finding trials of two agents.
    Lee BL; Fan SK
    J Biopharm Stat; 2012; 22(4):802-18. PubMed ID: 22651116
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An approach to meta-analysis of dose-finding studies.
    Zohar S; Katsahian S; O'Quigley J
    Stat Med; 2011 Jul; 30(17):2109-16. PubMed ID: 21344473
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A simple Bayesian decision-theoretic design for dose-finding trials.
    Fan SK; Lu Y; Wang YG
    Stat Med; 2012 Dec; 31(28):3719-30. PubMed ID: 22763943
    [TBL] [Abstract][Full Text] [Related]  

  • 20. phase1RMD: An R package for repeated measures dose-finding designs with novel toxicity and efficacy endpoints.
    Yin J; Du Y; Qin R; Shen S; Mandrekar S
    PLoS One; 2021; 16(9):e0256391. PubMed ID: 34473708
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.